Spatial collocation and venture capital in the US biotechnology industry

2011 ◽  
Vol 40 (9) ◽  
pp. 1188-1199 ◽  
Author(s):  
Christos Kolympiris ◽  
Nicholas Kalaitzandonakes ◽  
Douglas Miller
Keyword(s):  
Venture Capital ◽  
Biotechnology Industry ◽  
The Us

scholarly journals 2003: What lessons for European biotechnology?

10.5912/jcb87 ◽  
2004 ◽  
Vol 10 (4) ◽  
Author(s):  
M S Fazeli
Keyword(s):  
Venture Capital ◽  
Biotechnology Industry ◽  
Equity Capital ◽  
Public Markets ◽  
Level Of Activity ◽  
Risk Appetite ◽  
The Us ◽  
The Usa ◽  
Liberal Attitude ◽  
Biotechnology Sector

The biotech sector had a sizzling year last year, raising US$19bn in cash globally. This paper looks at the performance of the biotechnology sector on both sides of the Atlantic in terms of financing activity. Financing activity in the European biotechnology industry is still a long way off from the USA, with public fundraising only reaching the level that the USA had in 1997 and venture capital financings getting close to the US levels of 1994–95. This suggests that at least another five to eight years is needed before there is even a chance to get near where the USA is today. However, the sheer size of the US equity capital market and its liberal attitude to fundraisings and higher-risk appetite is likely to mean that European biotechs will never catch up with the USA, even if our science (across the whole of Europe) is as good. This does not mean that Europe cannot have a thriving biotechnology industry. Indeed, the current level of activity in the venture capital and public markets suggests that Europe is only just getting serious on biotechnology.

scholarly journals Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry

1969 ◽  
Vol 15 (4) ◽  
Author(s):  
J Leslie Glick
Keyword(s):  
Venture Capital ◽  
Early Stage ◽  
Coming Of Age ◽  
Personalised Medicine ◽  
Biotechnology Industry ◽  
Long Run ◽  
Start Up ◽  
The Us ◽  
Biotechnology Companies ◽  
Long Term Trends

Venture capital (VC) funding of US biotechnology companies was analysed relative to total VC investments placed in US companies from 1995 to 2007. During those years, except for a spike because of the dot-com bubble from 1999 to 2001, VC funding of US biotechnology companies grew at a faster rate percentagewise than total VC funding of US companies, with respect to annual dollars invested, number of deals closed and the mean dollar investment. Start-up and early-stage VC funding of US biotechnology companies also grew at a faster rate percentagewise, with respect to all three parameters, than total start-up and early-stage VC funding of US companies. It was further observed that long-term trends in the availability of VC for biotechnology do not appear to be affected by perturbations in the financial markets and short-term fluctuations in the availability of VC. It was concluded that the biotechnology industry should continue to attract VC over the long run particularly because of the emerging impact of personalised medicine and the coming of age of bioenergy.

Pioneering in Asia With the US Venture Capital Model

2012 ◽  
Vol 29 (6) ◽  
pp. 52-55
Author(s):  
Erik Jan Marinissen
Keyword(s):  
Venture Capital ◽  
The Us

The rise of venture capital and biotechnology in the US and Europe

2005 ◽  
Vol 23 (6) ◽  
pp. 672-676 ◽  
Author(s):  
Douglas P Lee ◽  
Mark D Dibner
Keyword(s):  
Venture Capital ◽  
The Us

What you give is what you get: Investment in European biotechnology

1969 ◽  
Vol 12 (4) ◽  
Author(s):  
William Bains
Keyword(s):  
Initial Public Offering ◽  
North American ◽  
Biotechnology Industry ◽  
Lower Amount ◽  
American Industry ◽  
Cause And Effect ◽  
The North ◽  
The Us ◽  
European Industry ◽  
Public Offering

The European biotechnology industry receives less funding, and less funding per company, than the North American industry, especially at the sensitive early stages of company development, and the European industry is substantially smaller in terms of employment, products and capitalisation than the US industry. The cause and effect of this relationship are explored in this paper. It is shown that if the European industry is immature it is because its growth has been slower, most probably because of low investment levels, and that the relatively lower value of biotech companies at initial public offering (IPO) is a result of the lower amount of investment they receive, not a reason for. This suggests that poor investment levels are a primary cause of the small size of European biotech companies and the European industry as a whole, not an effect of it. Investor mistrust and investment mechanisms are plausible reasons for this under-investment.

Sign in / Sign up

Export Citation Format

Share Document